FDA asks GSK to revise label of 2 asthma drugs

06/2/2010 | American City Business Journals · Reuters

The FDA ordered GlaxoSmithKline to change the warning label of asthma drugs Serevent and Advair. The long-acting beta-agonists have been shown to worsen asthma symptoms and result in hospitalization or death when used as a stand-alone treatment, according to the agency.

View Full Article in:

American City Business Journals · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY